Update December 2017

Thanks to the successful financing round of CHF 7.7 million in May 2017, the InnoMedica team has achieved significant progress with Talidox in recent months and further developed a new liposomal application in the field of neurodegenerative diseases into a…

June 2017: Annual general meeting 2017

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2017. The Annual General Meeting will be held on Tuesday, June 20th  2017 at 04:30 pm (doors open at 04:15 pm) in the conference room of the OBC Suisse AG…

March-May 2017: Capital increase with public offering

March-May 2017: Capital increase with public offering

Join our oncology-project: Capital increase with public offer of 75,000 bearer shares / CHF 7,706,250 The subscription ends May 31, 2017. Share price is CHF 102.75 per new share (minimum 150 shares). Visit us at an investor event in Bern, Zurich or…

Fall term update 2016

Fall term update 2016

Thanks to the successful financing round of CHF 3.3 million in May 2016, the InnoMedica team was able to further advance the Talidox project in the last few months and to gain fundamental progress in the fields of preclinical, clinical…

Getting Talidox to the cancer patients

Getting Talidox to the cancer patients

InnoMedica has made a good start to the New Year and is getting Talidox at full speed into the clinics. InnoMedica and SAKK are ready for the registration of the clinical trial phase I: After acquiring the required financial funding…

June 2016: Annual general meeting 2016

June 2016: Annual general meeting 2016

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2016. The Annual General Meeting will be held on Tuesday, June 21st  2016 at 04:30 pm (doors open at 04:15 pm) in the conference room of the OBC Suisse AG…

Talidox better than caelyx/doxil and free doxorubicin

Talidox better than caelyx/doxil and free doxorubicin

In the in vivo study of the Mario Negri Institute, the effect of different treatments on tumor size in mice was examined, whereby in addition to an untreated control group (black) our product Talidox (turquoise) was compared with the therapies currently used…

March-May 2016: Capital increase with public offer

March-May 2016: Capital increase with public offer

Today chemotherapy remains the standard medicine for treating cancer. Yet treatment with this medicine means drugs interact with the entire body – causing intense side effects. Our medicine packages a chemotherapy drug inside a liposome, and by imitating the natural…

April 2016: Innomedica at swiss Biotech Day in Basel

April 2016: Innomedica at swiss Biotech Day in Basel

April 12th, 2016, InnoMedica will participate at the Swiss Biotech Day. We will present our project Talidox in the Analyst & Investor track with regard to capital increase beginning until May 31, 2016. Come and visit us at our booth –…

January 2016: Positive results from efficacy study

January 2016: Positive results from efficacy study

After the promising results from biodistribution and pharmacokinetics in autumn 2015, data form the efficacy study by Mario Negri Institute can now be presented. In an in vivo study with five mice per group, an increased efficacy could be demonstrated by a…